Nasdaq:US$18.56 (-0.72) | HKEX:HK$29.35 (-0.85) | AIM:£2.90 (-0.15)
Search
Announcements
12345678910
11
12131415
found Documents: 719
Announcements & Press Releases, Oncology / Immunology | 23 Jul 2015

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med
London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui
Read More
PDF
Announcements & Press Releases, Other Ventures | 17 Jul 2015

20-year invention patent granted on Chi-Med's best selling prescription drug
London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven
Read More
a150717
Announcements & Press Releases, Regulatory Notice | 6 Jul 2015

Notice of Announcement of 2015 Interim Results
London: Monday, 6 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) will be announcing its interim results for the six months ended 30 June 2015 on Tuesday, 28 July 2015. An analyst presentation will be held at 9:00 am on the same d
Read More
a150706
Announcements & Press Releases, Regulatory Notice | 29 Jun 2015

Blocklisting Six Monthly Return
London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM)announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of
Read More
a150629
Announcements & Press Releases, Oncology / Immunology | 1 Jun 2015

Savolitinib (AZD6094) preliminary Phase Ib clinical data in lung cancer presented at the 2015 ASCO Annual Meeting
London: Monday, 1 June 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM), today announces that AstraZeneca AB (publ) (“AstraZeneca”), Hutchison MediPharma Limited’s (“HMP”) collaboration partner, presented preliminary data f
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 May 2015

Positive fruquintinib proof-of-concept study results trigger payments from Lilly
London: Wednesday, 13 May 2015: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned drug R&D company, is set to receive a total of US$18 million in payments, in the second quarter of 2015, from Eli Lilly and
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Apr 2015

Total Voting Rights
London: Thursday, 30 April 2015: For information purposes, Chi-Med hereby notifies the market that as at 30 April 2015, the issued share capital of Chi-Med consisted of 53,299,964 ordinary shares of US$1.00 each, with each share carrying one right to
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 24 Apr 2015

Results of Annual General Meeting
London: Friday, 24 April 2015: Chi-Med today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on 24 April 2015 were duly passed. Please download the PDF.  
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 22 Apr 2015

Director's Shareholding
London: Wednesday, 22 April 2015: Chi-Med received notification on 22 April 2015 that Mr Christopher Nash, Independent Non-executive Director, has purchased 1,388 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP18.00 pe
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 16 Apr 2015

Director's Shareholding
London: Thursday, 16 April 2015: Chi-Med received notification on 16 April 2015 that Simon To, Executive Director and Chairman, has purchased 28,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP15.85 per share on 15
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 13 Apr 2015

Director's Shareholding
London: Monday, 13 April 2015: Chi-Med received notification on 13 April 2015 that Simon To, Executive Director and Chairman, has purchased 25,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP14.215 per share on 10 A
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 8 Apr 2015

Directors' Shareholding
London: Wednesday, 8 April 2015: Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Apr 2015

Directors' Shareholding
London: Wednesday, 1 April 2015: Chi-Med received notifications on 1 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase Numbe
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Apr 2015

Exercise of Options
London: Wednesday, 1 April 2015: Chi-Med announces that it has issued 64,038 ordinary shares of US$1.00 each (the "Shares") following the exercise of options by Mr Johnny Cheng, Executive Director and Chief Financial Officer of Chi-Med, at an exercis
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Mar 2015

The first proof-of-concept trial of fruquintinib achieves primary efficacy endpoint
London: Monday, 30 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, successfully achieved the primary endpoint in the first proof-of-concept ("POC") trial of fruquintinib in pati
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Mar 2015

2014 Annual Report and Notice of Annual General Meeting
London: Monday, 23 March 2015: Chi-Med today announces that its 2014 Annual Report together with the Notice of Annual General Meeting and the Proxy Form have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 18 Mar 2015

TR-1: Notification of major interest in shares
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Mar 2015

Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer; Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer
London: Friday, 6 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 26 Feb 2015

Final Results for the year ended 31 December 2014
For the complete release, please download the PDF. -- Break-out year for Drug R&D Division with 16 clinical studies on 7 drug candidates; 10 potential Breakthrough Therapy indications; as well as record China Healthcare Division revenues and
Read More
View Announcement (PDF)
Announcements & Press Releases, Other Ventures, Press Releases | 29 Jan 2015

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China
Press Release -  London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"),
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 26 Jan 2015

Notice of Announcement of 2014 Final Results
London: Monday, 26 January 2015: Chi-Med will be announcing its final results for the year ended 31 December 2014 on Thursday, 26 February 2015. An analyst presentation will be held at 9:00 am on the same day at Citigate Dewe Rogerson, 3 London Wall
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2014

Total Voting Rights
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Dec 2014

Blocklisting Six Monthly Return
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 15 Dec 2014

Initiation of fruquintinib Phase III registration study in colorectal cancer
London: Monday, 15 December 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated FRESCO, a Phase III registration study in colorectal cancer (“CRC”) patients in China, for
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 20 Nov 2014

Director's Shareholding
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Oct 2014

Total Voting Rights
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 7 Oct 2014

Drug R&D Update Briefing for Analysts and Investors on 17 October 2014
Press Release -  London: Tuesday, 7 October 2014:  Chi-Med today announces that it will host a briefing to update analysts and investors on Hutchison MediPharma Limited (“HMP”), its majority owned pharmaceutical R&D division, in London o
Read More
View Announcement (PDF)
Announcements & Press Releases, Other Ventures, Press Releases | 1 Oct 2014

Chi-Med and Merck Serono sign co-promotion agreement
Press Release -  London: Wednesday, 1 October 2014: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company L
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 19 Sep 2014

TR-1: Notification of major interest in shares
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 21 Aug 2014

Patient enrolment completed ahead of schedule for fruquintinib's Phase II study in colorectal cancer
London: Thursday, 21 August 2014: Chi-Med, today announces that Hutchison MediPharma Limited (“HMP”), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in colorectal c
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 Aug 2014

HMPL-004 NATRUL-3 interim analysis result
London: Wednesday, 13 August 2014: Nutrition Science Partners Limited (“NSP”), a 50/50 joint venture between Chi-Med and Nestlé Health Science SA, today announces that a planned interim analysis was conducted on NATRUL-3, the global Phase III in
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 29 Jul 2014

Interim Results for the Six Months Ended 30 June 2014
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2014

Total Voting Rights
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2014

Blocklisting Six Monthly Return
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 26 Jun 2014

Notice of Announcement of 2014 Interim Results
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 25 Jun 2014

Chi-Med Refinancing of Existing Loan Facility
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Jun 2014

Initiation of Phase I clinical trial of novel Syk Inhibitor HMPL - 523 for autoimmune diseases
London: Wednesday, 18 June 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), the majority owned R&D company of Chi-Med, has initiated the first-in-human Phase I clinical trial of HMPL-523 in Australia.  HMPL-523 is a n
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Jun 2014

Initiation of fruquintinib Phase II study in non-small cell lung cancer
London: Thursday, 5 June 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated a Phase II clinical trial in non-small cell lung cancer (“NSCLC”) patients in China for fruqui
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Jun 2014

Director's Shareholding
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jun 2014

Exercise of Options
View Announcement (PDF)
Announcements & Press Releases, Other Ventures | 30 May 2014

Chi-Med and Shanghai Traditional Chinese Medicine expand commercial cooperation
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 May 2014

Initiation of AZD6094 (HMPL-504/volitinib) Global Phase II Study in Papillary Renal Cell Carcinoma
London: Friday, 23 May 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), Chi- Med’s majority owned R&D company, and AstraZeneca AB (publ) (“AstraZeneca”) have initiated a global Phase II study to evaluate the effi
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 22 May 2014

Phase I clinical data for selective VEGFR, c-Met and VEGFR/FGFR inhibitors to be presented at the 2014 ASCO Annual Meeting
London: Thursday, 22 May 2014: Chi-Med today announces that data from recent Phase I and Phase Ib clinical studies by Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, will be presented at the 50th Annual Meeting of the Am
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 8 May 2014

Results of Annual General Meeting
View Announcement (PDF)
Announcements & Press Releases, Other Ventures | 17 Apr 2014

Chi-Med and Sinopharm complete regulatory approval for the establishment of new China drug distribution and marketing Joint Venture
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Apr 2014

Initiation of fruquintinib Phase II study in colorectal cancer
London: Friday, 4 April 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated a Phase II clinical trial in colorectal cancer (“CRC”) patients in China for fruquintinib (HMPL
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Apr 2014

Presentations of volitinib and epitinib data at the 2014 AACR Annual Meeting
London: Friday, 4 April 2014: Chi-Med today announces that data from certain preclinical and clinical studies by Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, will be presented at the 105th Annual Meeting of the Americ
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Mar 2014

2013 Annual Report and Notice of Annual General Meeting
View Announcement (PDF)
Announcements & Press Releases, Group | 18 Feb 2014

Final Results for the year ended 31 December 2013
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 13 Feb 2014

TR-1: Notification of major interest in shares
View Announcement (PDF)
12345678910
11
12131415